You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 4.2% | 4.4% |
Div Cover | 2.6 | 2.6 |
Op Mrgn | 12.8% | 28.5% |
ROCE | 47.1% |
Latest | Forecast | |
---|---|---|
P/E | 9.1 | 0.0 |
PEG | 3.3 | 2.7 |
Price / Revenue | 1.9 | 1.8 |
Price / Book value | 4.6 |
Latest | Forecast | |
---|---|---|
Revenue | 3.5% | -2.2% |
PBT | -42.7% | n/a |
EPS | 2.7% | -6.1% |
DPS | 5.2% | -2.1% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
2021-12-31 | 24,696.00 | 3,599.00 | 90.56p | 22.2 | -1.0 | -22% | 80.00p | 4.0% |
2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.2 | 54% | 44.00p | 3.1% |
2023-12-31 | 30,328.00 | 6,064.00 | 155.10p | 9.4 | 0.8 | 11% | 58.00p | 4.0% |
2024-12-31 | 31,376.00 | 3,477.00 | 159.30p | 8.5 | 3.1 | 3% | 61.00p | 4.5% |
London close: Stocks rise as trade tensions continue Sharecast News | 05 Feb |
---|---|
GSK ups five-year sales outlook, unveils $2bn buyback Sharecast News | 05 Feb |
GSK's pre-filled shingles vaccine accepted for review by EMA Sharecast News | 27 Jan |
Director/PDMR Shareholding | 13-Feb-25 15:30 |
---|---|
Director/PDMR Shareholding | 11-Feb-25 15:30 |
Final Results | 05-Feb-25 21:38 |
Total Voting Rights | 03-Feb-25 16:48 |
Depemokimab dual filing in China and Japan | 28-Jan-25 07:05 |